Home Free Dental Care States Medicaid Submit Procedure List Foreign Research Contact

Dental Research Programs in Jerusalem Israel

A Clinical Study of the Use of Brushite as Primary Stabilizer in Immediate Dental Implantation

TThis study is not yet open for patient recruitment

Verified by Hadassah Medical Organization September 2006

Sponsors and Collaborators: Hadassah Medical Organization
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00299585


Objective: evaluation of “PD” VitalOs Cement,an injectable brushite,as stabilizer of dental implant and potential sorce for bone augmentation.

Methods: 40 patients needing dental implants will be treated where needed with “PD” VitalOs Cement gapping halve of their sites where as the other halve will be gapped with Bio oss demineralized bone and bioguide membrane.

Condition Intervention Phase
Alveolar Ridge Augmentation
Mandibular Ridge Augmentation
Maxillary Ridge Augmentation
Synthetic Implants for Rebuilding the Alveolar Ridge.
Procedure: using calcium phosphate bone cement with dental implants

Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Expanded Access Assignment, Safety/Efficacy Study

Official Title: phase2 Clinical Study on the Efficacy of Injectable Brushite Bone Cement in Bone Augmentation and Dental Implant Stabilization.

Further study details as provided by Hadassah Medical Organization:
Primary Outcomes: Xray evaluation of osseointegration; periosens for osseointegration; clinical stability after 6 months
Secondary Outcomes: long term followup for osseointegration clinical and Xray
Expected Total Enrollment:  40

Study start: October 2006

Bone fractures or bone loss in specific sites are cases where a bone graft is sometimes needed to provide bone augmentation. For bone fractures, these are typically metaphyseal or maxillo-facial fractures with risk of malunion or non-union. Bone loss can happen under various circumstances: it can be a consequence of a systemic disease like osteoporosis or of a surgical intervention like the extraction of a tooth or the removal of a bone cyst or tumor.

When a bone graft is required the gold standard still widely used is autogenous cancellous bone. However, the graft harvesting procedure is invasive and increases patient morbidity (lengthened surgical procedure, increased risk of infection). Moreover, the availability of autologous grafts is limited, especially in elderly patients. This has been the rationale for studying alternative sources for bone grafts.

The first alternative is allografts: they are usually obtained from cadavers. The advantages include elimination of a patient donor site, hence reduced surgical time and decreased blood loss and risk of infection. The principal shortcomings are the availability, the possible rejection of the graft and the risk of disease transmission.

Grafts of animal origin (xenografts) are also an option, even though not totally risk-free when it comes to disease transmission.

A third alternative to autologous bone is to use synthetic materials. Extensive research has been performed to develop such materials since the 80’s. The majority of them are based on calcium phosphate compounds, made up of the same ions as those of the natural mineral phase of bone. These products are readily available, eliminate the risk of disease transmission or immunogenic response (allografts) and bypass the need for an additional surgical procedure (autografts). These materials are presented under either of the three forms: granules, pre-formed blocks or cements.

Granules and pre-formed blocks are generally made up of β-TCP, Hydroxyapatite (HA), or a mix of both. Depending mainly on their chemical composition, their manufacturing process and their porosity, they degrade more or less rapidly.

Calcium phosphate cements consist generally of a liquid and a powder which harden upon mixing. The final product phase can be hydroxyapatite, or another calcium phosphate phase like dahllite or brushite. The advantage of cements over pre-formed blocks is that they can be injected, shaped and hardened in situ, ensuring optimum bone-implant contact and minimally invasive surgery. Once hardened, they exhibit cohesive properties that granules cannot provide. Most of the calcium phosphate cements available on the market are hydroxyapatite cements. However, for some applications like periodontitis or peri-implant gap filling, their resorption rate is too slow, hampering their clinical applicability for these indications. the advantage of the brushite phase in the hardened cement is that it degrades faster than hydroxyapatite, allowing a more rapid bone regeneration. The purpose of this study is to evaluate the efficacy of “PD” VitalOs Cement as a primary stabilizer and bone augmenting source in dental implantology.


Genders Eligible for Study:  Both

Accepts Healthy Volunteers


Inclusion Criteria:

  • partial or full edentulous patients who need dental implants to support a prosthesis

Exclusion Criteria:

  • patients with uncontrolled diabetes
  • chemotherapy
  • immune suppressed
  • radiotherapy to head and neck in the last five years

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00299585

Michael M Perez Davidi, DMD      00 972 3 9244859    michaelpd@hadassah.org.il
Ervin I Weiss, DMD      00 972 2 6776151    ervinw@md.huji.ac.il

Hadassah Medical Organization,, Jerusalem,,  91120,  Israel

Study chairs or principal investigators

Michael M Perez Davidi, DMD,  Study Chair,  Hadassah Medical Organization   
Nardi Caspi, DMD,  Principal Investigator,  Hadassah Medical Organization   

More Information


Pittet C, Lemaitre J. Mechanical characterization of brushite cements: a Mohr circles' approach. J Biomed Mater Res. 2000;53(6):769-80.

Publications that report results of this study

Charriere E, Terrazzoni S, Pittet C, Mordasini PH, Dutoit M, Lemaitre J, Zysset PH. Mechanical characterization of brushite and hydroxyapatite cements. Biomaterials. 2001 Nov;22(21):2937-45.

Study ID Numbers:  191059 HMO-CTIL
Last Updated:  September 14, 2006
Record first received:  March 5, 2006
ClinicalTrials.gov Identifier:  NCT00299585
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on 2006-10-19

[Home]   [State Directory]   [Free Treatment]   [Foreign Directory]   [Contact]   [Submit Research]  
Dentistry Research Programs Directory
Jerusalem Israel Europe
A Featured part of
Dental Research Programs featured in Dental Health Library
Oral Health Research Issues in Dentistry
All rights reserved - 1999-2014
Powered by DentMedHost